

08 December 2017

Eagle Begins Shipment of Omni Innovation's Diabetes Product

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on its ~40% portfolio company, Omni Innovation, the medical technology company focused on medical nutrition.

Omni Innovation is pleased to announce that as part of its strategy to expand its distribution network for its patent protected pre-meal drink for type 2 diabetes, its Chinese partner, Eagle Health (ASX: EHH) has begun shipping the product in Xiamen and opened four diabetes education and experience stores.

Eagle Health exclusively manufactures, markets and distributes the Australian clinically proven pre-meal shake product for Type 2 diabetes and Pre-Type 2 diabetes throughout mainland China through the Company's extensive network of pharmacies and other retail outlets.

Xiamen recently became the ninth city in the world to launch the Change Diabetes Project ("Project"). The Project will study current incidence of diabetes in Xiamen, raise the awareness of the urban residents about diabetes, and assist the community to better jointly cope with the challenges of diabetes. The launch of Omni Innovation's pre-meal drink for type 2 diabetes is a significant milestone for this project, Eagle Health and Omni Innovation.

According to the International Diabetes Federation (IDF) 2017 Diabetes Atlas China has 114.4 million people with diabetes, projected to increase to 119.8 million in 2045. IDF estimate an additional 6.1 million people are undiagnosed, the highest globally. An aging and growing population and increasing obesity are the main drivers of this alarming trend that is particularly prevalent in urban Chinese locations.

Mr Zhang Mingwang, Managing Director of Eagle Health, said:

"We are honoured to be able to provide Type 2 diabetes sufferers in China such a world class and clinically validated solution to support them in their lifestyle intervention in order to manage this serious national health issue.

"Xiamen is our home city and the local authority focus on diabetes means Xiamen is a perfect place for us to begin our journey.

"We know that Chinese consumers and their Healthcare practitioners will recognise the clinical effectiveness and the high quality product developed in Australia and now produced by the trusted Eagle Health Brand."

The product will be sold in Pharmacies and Supermarkets in China at an affordable price to ensure maximum reach of sufferers.

Mr Philip Owens, CEO of Omni Innovation, said:

“We are delighted with the approach our Chinese partner, Eagle Health, and their ability to bring to market the pre-meal drink technology for Type 2 diabetes and Pre-Type 2 diabetes. We see China as an important part of our distribution strategy and look forward to Eagle’s success in building a significant medical nutrition franchise centred around our product.”

About Omni Innovation:

Omni Innovation creates unique and specialised medical nutrition products that can be used by people with chronic and lifestyle diseases. Omni's products are independently validated and supervised by Omni's expert collaborator network to ensure that customers have safe, effective and clinically tested products that provide benefit with scientific backing.

About Eagle Health Holdings Limited

Eagle Health Holdings Limited is a vertically integrated nutritional products business that aims to help people live healthier lives by developing, manufacturing, marketing and distributing a range of health food products and nutritional and dietary supplements under its own brand in China. The Company distributes its products through a broad range of channels, including pharmacies, health food stores, trading companies, supermarkets and online channels, covering 23 provinces and autonomous regions throughout China.

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in medical nutrition companies. EVE is an investment partner that wants to help build ground breaking and enduring technology with a preference for companies that have global scale.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

For more information:

Ben Rohr
Investment Director
+61 8 6465 5500
benr@eveinvestments.com.au